<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36466841</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Pathophysiological mechanisms of thrombosis in acute and long COVID-19.</ArticleTitle><Pagination><StartPage>992384</StartPage><MedlinePgn>992384</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">992384</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.992384</ELocationID><Abstract><AbstractText>COVID-19 patients have a high incidence of thrombosis, and thromboembolic complications are associated with severe COVID-19 and high mortality. COVID-19 disease is associated with a hyper-inflammatory response (cytokine storm) mediated by the immune system. However, the role of the inflammatory response in thrombosis remains incompletely understood. In this review, we investigate the crosstalk between inflammation and thrombosis in the context of COVID-19, focusing on the contributions of inflammation to the pathogenesis of thrombosis, and propose combined use of anti-inflammatory and anticoagulant therapeutics. Under inflammatory conditions, the interactions between neutrophils and platelets, platelet activation, monocyte tissue factor expression, microparticle release, and phosphatidylserine (PS) externalization as well as complement activation are collectively involved in immune-thrombosis. Inflammation results in the activation and apoptosis of blood cells, leading to microparticle release and PS externalization on blood cells and microparticles, which significantly enhances the catalytic efficiency of the tenase and prothrombinase complexes, and promotes thrombin-mediated fibrin generation and local blood clot formation. Given the risk of thrombosis in the COVID-19, the importance of antithrombotic therapies has been generally recognized, but certain deficiencies and treatment gaps in remain. Antiplatelet drugs are not in combination with anticoagulant treatments, thus fail to dampen platelet procoagulant activity. Current treatments also do not propose an optimal time for anticoagulation. The efficacy of anticoagulant treatments depends on the time of therapy initiation. The best time for antithrombotic therapy is as early as possible after diagnosis, ideally in the early stage of the disease. We also elaborate on the possible mechanisms of long COVID thromboembolic complications, including persistent inflammation, endothelial injury and dysfunction, and coagulation abnormalities. The above-mentioned contents provide therapeutic strategies for COVID-19 patients and further improve patient outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Jing, Wu, Xiang, Liu, Novakovic and Shi.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jing</LastName><ForeName>Haijiao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, The First Hospital, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, The First Hospital, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Mengqi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, The First Hospital, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Langjiao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hematology, The First Hospital, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novakovic</LastName><ForeName>Valerie A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Department of Research, VA Boston Healthcare System, Harvard Medical School, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Jialan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, The First Hospital, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research, VA Boston Healthcare System, Harvard Medical School, Boston, MA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010718">Phosphatidylserines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010718" MajorTopicYN="N">Phosphatidylserines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anti-inflammatory treatment</Keyword><Keyword MajorTopicYN="N">antithrombotic therapy</Keyword><Keyword MajorTopicYN="N">immunothrombosis</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>5</Day><Hour>4</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36466841</ArticleId><ArticleId IdType="pmc">PMC9709252</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.992384</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Farkouh ME, Stone GW, Lala A, Bagiella E, Moreno PR, Nadkarni GN, et al. . Anticoagulation in patients with COVID-19: JACC review topic of the week. J Am Coll Cardiol (2022) 79(9):917&#x2013;28. doi:&#xa0;10.1016/j.jacc.2021.12.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.12.023</ArticleId><ArticleId IdType="pmc">PMC8884342</ArticleId><ArticleId IdType="pubmed">35241226</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez D, Garc&#xed;a-Sanchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, et al. . Incidence of VTE and bleeding among 468Hospitalized patients with coronavirus disease 2019: A systematic review and meta-analysis. Chest (2021) 159(3):1182&#x2013;4691196. doi:&#xa0;10.1016/j.chest.2020.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.11.005</ArticleId><ArticleId IdType="pmc">PMC7670889</ArticleId><ArticleId IdType="pubmed">33217420</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansory EM, Srigunapalan S, Lazo-Langner A. Venous thromboembolism in hospitalized critical and noncritical COVID-19 patients: A systematic review and meta-analysis. TH Open (2021) 5(3):e286&#x2013;94. doi:&#xa0;10.1055/s-0041-1730967</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1730967</ArticleId><ArticleId IdType="pmc">PMC8260281</ArticleId><ArticleId IdType="pubmed">34240001</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost (2020) 4(7):1178&#x2013;91. doi:&#xa0;10.1002/rth2.12439</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12439</ArticleId><ArticleId IdType="pmc">PMC7537137</ArticleId><ArticleId IdType="pubmed">33043231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. . Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. N Engl J Med (2020) 383(2):120&#x2013;8. doi:&#xa0;10.1056/NEJMoa2015432</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donnell JS, Peyvandi F, Martin-Loeches I. Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Med (2021) 47(8):899&#x2013;902. doi:&#xa0;10.1007/s00134-021-06419-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06419-w</ArticleId><ArticleId IdType="pmc">PMC8164686</ArticleId><ArticleId IdType="pubmed">34052905</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt B, Tate AM, Gluck D, Rosenson RS, Goonewardena SN. Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19. Eur Heart J Cardiovasc Pharmacother (2022) 8(4):402&#x2013;5. doi:&#xa0;10.1093/ehjcvp/pvac014</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvac014</ArticleId><ArticleId IdType="pmc">PMC8903502</ArticleId><ArticleId IdType="pubmed">35179184</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquired pneumonia: Incidence, timing, risk factors, and association with short-term mortality. Circulation (2012) 125(6):773&#x2013;81. doi:&#xa0;10.1161/CIRCULATIONAHA.111.040766</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.111.040766</ArticleId><ArticleId IdType="pubmed">22219349</ArticleId></ArticleIdList></Reference><Reference><Citation>Palankar R, Greinacher A. Challenging the concept of immunothrombosis. Blood (2019) 133(6):508&#x2013;9. doi:&#xa0;10.1182/blood-2018-11-886267</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-11-886267</ArticleId><ArticleId IdType="pubmed">30733204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wienkamp AK, Erpenbeck L, Rossaint J. Platelets in the NETworks interweaving inflammation and thrombosis. Front Immunol (2022) 3:953129. doi:&#xa0;10.3389/fimmu.2022.953129</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.953129</ArticleId><ArticleId IdType="pmc">PMC9376363</ArticleId><ArticleId IdType="pubmed">35979369</ArticleId></ArticleIdList></Reference><Reference><Citation>Colling ME, Tourdot BE, Kanthi Y. Inflammation, infection and venous thromboembolism. Circ Res (2021) 128(12):2017&#x2013;36. doi:&#xa0;10.1161/CIRCRESAHA.121.318225</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.318225</ArticleId><ArticleId IdType="pmc">PMC8202069</ArticleId><ArticleId IdType="pubmed">34110909</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol (2013) 13(1):34&#x2013;45. doi:&#xa0;10.1038/nri3345</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3345</ArticleId><ArticleId IdType="pubmed">23222502</ArticleId></ArticleIdList></Reference><Reference><Citation>Bovill EG, van der Vliet A. Venous valvular stasis-associated hypoxia and thrombosis: What is the link? Annu Rev Physiol (2011) 73:527&#x2013;45. doi:&#xa0;10.1146/annurev-physiol-012110-142305</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-physiol-012110-142305</ArticleId><ArticleId IdType="pubmed">21034220</ArticleId></ArticleIdList></Reference><Reference><Citation>Jian D, Wang Y, Jian L, Tang H, Rao L, Chen K, et al. . METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications. Theranostics (2020) 10(20):8939&#x2013;56. doi:&#xa0;10.7150/thno.45178</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.45178</ArticleId><ArticleId IdType="pmc">PMC7415798</ArticleId><ArticleId IdType="pubmed">32802173</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol (2021) 18(9):666&#x2013;82. doi:&#xa0;10.1038/s41569-021-00552-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00552-1</ArticleId><ArticleId IdType="pmc">PMC8100938</ArticleId><ArticleId IdType="pubmed">33958774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner DD, Heger LA. Thromboinflammation: from atherosclerosis to COVID-19. Arterioscler Thromb Vasc Biol (2022) 42(9):1103&#x2013;12. doi:&#xa0;10.1161/ATVBAHA.122.317162</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.122.317162</ArticleId><ArticleId IdType="pmc">PMC9420806</ArticleId><ArticleId IdType="pubmed">35861953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng H, Havervall S, Rosell A, Aguilera K, Parv K, von Meijenfeldt FA, et al. . Circulating markers of neutrophil extracellular traps are of prognostic value in patients with COVID-19. Arterioscler Thromb Vasc Biol (2021) 41(2):988&#x2013;94. doi:&#xa0;10.1161/ATVBAHA.120.315267</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.315267</ArticleId><ArticleId IdType="pmc">PMC7837697</ArticleId><ArticleId IdType="pubmed">33267662</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care (2020) 24(1):360. doi:&#xa0;10.1186/s13054-020-03077-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03077-0</ArticleId><ArticleId IdType="pmc">PMC7301352</ArticleId><ArticleId IdType="pubmed">32552865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowery SA, Sariol A, Perlman S. Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. Cell Host Microbe (2021) 29(7):1052&#x2013;62. doi:&#xa0;10.1016/j.chom.2021.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.05.004</ArticleId><ArticleId IdType="pmc">PMC8126603</ArticleId><ArticleId IdType="pubmed">34022154</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaraja S, Jain D, Kesavardhana S. Inflammasome regulation in driving COVID-19 severity in humans and immune tolerance in bats. J Leukoc Biol (2022) 111(2):497&#x2013;508. doi:&#xa0;10.1002/JLB.4COVHR0221-093RR</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.4COVHR0221-093RR</ArticleId><ArticleId IdType="pmc">PMC8242921</ArticleId><ArticleId IdType="pubmed">34057760</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou YW, Xie Y, Tang LS, Pu D, Zhu YJ, Liu JY, et al. . Therapeutic targets and interventional strategies in COVID-19: Mechanisms and clinical studies. Signal Transduct Target Ther (2021) 6(1):317. doi:&#xa0;10.1038/s41392-021-00733-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00733-x</ArticleId><ArticleId IdType="pmc">PMC8390046</ArticleId><ArticleId IdType="pubmed">34446699</ArticleId></ArticleIdList></Reference><Reference><Citation>Islamuddin M, Mustfa SA, Ullah SNMN, Omer U, Kato K, Parveen S. Innate immune response and inflammasome activation during SARS-CoV-2 infection. Inflammation (2022) 45(5):1849&#x2013;63. doi:&#xa0;10.1007/s10753-022-01651-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-022-01651-y</ArticleId><ArticleId IdType="pmc">PMC9371632</ArticleId><ArticleId IdType="pubmed">35953688</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q, Liu J, Zhao S, Gomez Castro MF, Laurent-Rolle M, Dong J, et al. . SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through c-type lectin receptors and tweety family member 2. Immunity (2021) 54(6):1304&#x2013;1319.e9. doi:&#xa0;10.1016/j.immuni.2021.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.05.006</ArticleId><ArticleId IdType="pmc">PMC8106883</ArticleId><ArticleId IdType="pubmed">34048708</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung PS, Hsieh SL. C-type lectins and extracellular vesicles in virus-induced NETosis. . J BioMed Sci (2021) 28(1):46. doi:&#xa0;10.1186/s12929-021-00741-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-021-00741-7</ArticleId><ArticleId IdType="pmc">PMC8193014</ArticleId><ArticleId IdType="pubmed">34116654</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung PS, Huang TF, Hsieh SL. Extracellular vesicles from CLEC2-activated platelets enhance dengue virus-induced lethality via CLEC5A/TLR2. Nat Commun (2019) 10(1):2402. doi:&#xa0;10.1038/s41467-019-10360-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10360-4</ArticleId><ArticleId IdType="pmc">PMC6546763</ArticleId><ArticleId IdType="pubmed">31160588</ArticleId></ArticleIdList></Reference><Reference><Citation>Youn YJ, Lee YB, Kim SH, Jin HK, Bae JS, Hong CW. Nucleocapsid and spike proteins of SARS-CoV-2 drive neutrophil extracellular trap formation. Immune Netw (2021) 21(2):e16. doi:&#xa0;10.4110/in.2021.21.e16</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2021.21.e16</ArticleId><ArticleId IdType="pmc">PMC8099611</ArticleId><ArticleId IdType="pubmed">33996172</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung PS, Yang SP, Peng YC, Sun CP, Tao MH, Hsieh SL. CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation. J BioMed Sci (2022) 29(1):52. doi:&#xa0;10.1186/s12929-022-00832-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-022-00832-z</ArticleId><ArticleId IdType="pmc">PMC9277873</ArticleId><ArticleId IdType="pubmed">35820906</ArticleId></ArticleIdList></Reference><Reference><Citation>Wielgat P, Narejko K, Car H. SARS-CoV-2 attacks in the brain: Focus on the sialome. Cells (2022) 11(9):1458. doi:&#xa0;10.3390/cells11091458</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11091458</ArticleId><ArticleId IdType="pmc">PMC9104523</ArticleId><ArticleId IdType="pubmed">35563764</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: The current evidence and treatment strategies. Front Immunol (2020) 11:1708. doi:&#xa0;10.3389/fimmu.2020.01708</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01708</ArticleId><ArticleId IdType="pmc">PMC7365923</ArticleId><ArticleId IdType="pubmed">32754163</ArticleId></ArticleIdList></Reference><Reference><Citation>Melms JC, Biermann J, Huang H, Wang Y, Nair A, Tagore S, et al. . A molecular single-cell lung atlas of lethal COVID-19. Nature (2021) 595(7865):114&#x2013;9. doi:&#xa0;10.1038/s41586-021-03569-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03569-1</ArticleId><ArticleId IdType="pmc">PMC8814825</ArticleId><ArticleId IdType="pubmed">33915568</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from wuhan, China. Intensive Care Med (2020) 46(5):846&#x2013;8. doi:&#xa0;10.1007/s00134-020-05991-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol (2020) 20(7):389&#x2013;91. doi:&#xa0;10.1038/s41577-020-0343-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0343-0</ArticleId><ArticleId IdType="pmc">PMC7240244</ArticleId><ArticleId IdType="pubmed">32439870</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorog DA, Storey RF, Gurbel PA, Tantry US, Berger JS, Chan MY, et al. . Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the international COVID-19 thrombosis biomarkers colloquium. Nat Rev Cardiol (2022) 19(7):475&#x2013;95. doi:&#xa0;10.1038/s41569-021-00665-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00665-7</ArticleId><ArticleId IdType="pmc">PMC8757397</ArticleId><ArticleId IdType="pubmed">35027697</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. . An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med (2020) 26(10):1636&#x2013;43. doi:&#xa0;10.1038/s41591-020-1051-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. . C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J (2021) 42(23):2270&#x2013;9. doi:&#xa0;10.1093/eurheartj/ehaa1103</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa1103</ArticleId><ArticleId IdType="pmc">PMC7928982</ArticleId><ArticleId IdType="pubmed">33448289</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernysh IN, Nagaswami C, Kosolapova S, Peshkova AD, Cuker A, Cines DB, et al. . The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli. Sci Rep (2020) 10(1):5112. doi:&#xa0;10.1038/s41598-020-59526-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-59526-x</ArticleId><ArticleId IdType="pmc">PMC7083848</ArticleId><ArticleId IdType="pubmed">32198356</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolberg AS, Aleman MM, Leiderman K, Machlus KR. Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited. Anesth Analg (2012) 114(2):275&#x2013;85. doi:&#xa0;10.1213/ANE.0b013e31823a088c</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0b013e31823a088c</ArticleId><ArticleId IdType="pmc">PMC3264782</ArticleId><ArticleId IdType="pubmed">22104070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallez Y, Huber P. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim Biophys Acta (2008) 1778(3):794&#x2013;809. doi:&#xa0;10.1016/j.bbamem.2007.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2007.09.003</ArticleId><ArticleId IdType="pubmed">17961505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. . Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care (2020) 24(1):422. doi:&#xa0;10.1186/s13054-020-03120-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03120-0</ArticleId><ArticleId IdType="pmc">PMC7356137</ArticleId><ArticleId IdType="pubmed">32660650</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraga-Silva RA, Da Silva DG, Montecucco F, Mach F, Stergiopulos N, da Silva RF, et al. . The angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases. Thromb Haemost (2012) 108(6):1089&#x2013;96. doi:&#xa0;10.1160/TH12-06-0396</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH12-06-0396</ArticleId><ArticleId IdType="pubmed">23093373</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: Challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood (2019) 133(9):906&#x2013;18. doi:&#xa0;10.1182/blood-2018-11-882993</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-11-882993</ArticleId><ArticleId IdType="pubmed">30642917</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmon CT. Coagulation inhibitors in inflammation. Biochem Soc Trans (2005) 33(Pt 2):401&#x2013;5. doi:&#xa0;10.1042/BST0330401</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0330401</ArticleId><ArticleId IdType="pubmed">15787615</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin FA, Murphy RP, Cummins PM. Thrombomodulin and the vascular endothelium: Insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol (2013) 304(12):H1585&#x2013;97. doi:&#xa0;10.1152/ajpheart.00096.2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00096.2013</ArticleId><ArticleId IdType="pmc">PMC7212260</ArticleId><ArticleId IdType="pubmed">23604713</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito T, Thachil J, Asakura H, Levy JH, Iba T. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care (2019) 23(1):280. doi:&#xa0;10.1186/s13054-019-2552-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2552-0</ArticleId><ArticleId IdType="pmc">PMC6694689</ArticleId><ArticleId IdType="pubmed">31416465</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin RC, Voetsch B, Loscalzo J. Endogenous mechanisms of inhibition of platelet function. Microcirculation (2005) 12(3):247&#x2013;58. doi:&#xa0;10.1080/10739680590925493</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10739680590925493</ArticleId><ArticleId IdType="pubmed">15814434</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, L&#xfc;scher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J (2020) 41(32):3038&#x2013;44. doi:&#xa0;10.1093/eurheartj/ehaa623</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa623</ArticleId><ArticleId IdType="pmc">PMC7470753</ArticleId><ArticleId IdType="pubmed">32882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med (2010) 38(2Suppl):S26&#x2013;34. doi:&#xa0;10.1097/CCM.0b013e3181c98d21</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181c98d21</ArticleId><ArticleId IdType="pubmed">20083910</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh JD, Hoofnagle MH, Bamezai S, Oxendine M, Lim L, Hall JD, et al. . Hemodynamic regulation of perivalvular endothelial gene expression prevents deep venous thrombosis. J Clin Invest (2019) 129(12):5489&#x2013;500. doi:&#xa0;10.1172/JCI124791</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI124791</ArticleId><ArticleId IdType="pmc">PMC6877343</ArticleId><ArticleId IdType="pubmed">31710307</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks EG, Trotman W, Wadsworth MP, Taatjes DJ, Evans MF, Ittleman FP, et al. . Valves of the deep venous system: an overlooked risk factor. Blood (2009) 114(6):1276&#x2013;9. doi:&#xa0;10.1182/blood-2009-03-209981</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-03-209981</ArticleId><ArticleId IdType="pmc">PMC2723019</ArticleId><ArticleId IdType="pubmed">19436051</ArticleId></ArticleIdList></Reference><Reference><Citation>Radermecker C, Detrembleur N, Guiot J, Cavalier E, Henket M, d'Emal C, et al. . Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19. J Exp Med (2020) 217(12):e20201012. doi:&#xa0;10.1084/jem.20201012</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201012</ArticleId><ArticleId IdType="pmc">PMC7488867</ArticleId><ArticleId IdType="pubmed">32926097</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaumenhaft R, Enjyoji K, Schmaier AA. Vasculopathy in COVID-19. Blood (2022) 140(3):222&#x2013;35. doi:&#xa0;10.1182/blood.2021012250</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021012250</ArticleId><ArticleId IdType="pmc">PMC8736280</ArticleId><ArticleId IdType="pubmed">34986238</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G, et al. . The ADAMTS13-von willebrand factor axis in COVID-19 patients. J Thromb Haemost (2021) 19(2):513&#x2013;21. doi:&#xa0;10.1111/jth.15191</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15191</ArticleId><ArticleId IdType="pmc">PMC7753796</ArticleId><ArticleId IdType="pubmed">33230904</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinelli N, Montagnana M, Pizzolo F, Friso S, Salvagno GL, Forni GL, et al. . A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19. Thromb Res (2020) 193:170&#x2013;2. doi: 10.1016/j.thromres.2020.07.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.07.034</ArticleId><ArticleId IdType="pmc">PMC7367811</ArticleId><ArticleId IdType="pubmed">32707276</ArticleId></ArticleIdList></Reference><Reference><Citation>Favaloro EJ, Henry BM, Lippi G. Increased VWF and decreased ADAMTS-13 in COVID-19: Creating a milieu for (Micro) thrombosis. Semin Thromb Hemost (2021) 47(4):400&#x2013;18. doi:&#xa0;10.1055/s-0041-1727282</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1727282</ArticleId><ArticleId IdType="pubmed">33893632</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenyves BG, Mehta A, Kays KR. MGH COVID-19 collection &amp; processing team, Goldberg MB, hacohen n, filbin MR. plasma p-selectin is an early marker of thromboembolism in COVID-19. Am J Hematol (2021). doi:&#xa0;10.1101/2021.07.10.21260293</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.10.21260293</ArticleId><ArticleId IdType="pmc">PMC8616847</ArticleId><ArticleId IdType="pubmed">34622480</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett TJ, Bilaloglu S, Cornwell M, Burgess HM, Virginio VW, Drenkova K, et al. . Platelets contribute to disease severity in COVID-19. J Thromb Haemost (2021) 19(12):3139&#x2013;53. doi:&#xa0;10.1111/jth.15534</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15534</ArticleId><ArticleId IdType="pmc">PMC8646651</ArticleId><ArticleId IdType="pubmed">34538015</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett TJ, Lee AH, Xia Y, Lin LH, Black M, Cotzia P, et al. . Platelet and vascular biomarkers associate with thrombosis and death in coronavirus disease. Circ Res (2020) 127(7):945&#x2013;7. doi:&#xa0;10.1161/CIRCRESAHA.120.317803</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317803</ArticleId><ArticleId IdType="pmc">PMC7478197</ArticleId><ArticleId IdType="pubmed">32757722</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark K, Philippi V, Stockhausen S, Busse J, Antonelli A, Miller M, et al. . Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood (2016) 128(20):2435&#x2013;49. doi:&#xa0;10.1182/blood-2016-04-710632</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-04-710632</ArticleId><ArticleId IdType="pmc">PMC5147023</ArticleId><ArticleId IdType="pubmed">27574188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J, Song B, Xie X, Li X, Chen Z, Wang Z, et al. . Inflammation in cerebral venous thrombosis. Front Immunol (2022) 13:833490. doi:&#xa0;10.3389/fimmu.2022.833490</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.833490</ArticleId><ArticleId IdType="pmc">PMC9013750</ArticleId><ArticleId IdType="pubmed">35444662</ArticleId></ArticleIdList></Reference><Reference><Citation>Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al. . Platelet gene expression and function in patients with COVID-19. Blood (2020) 136(11):1317&#x2013;29. doi:&#xa0;10.1182/blood</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood</ArticleId><ArticleId IdType="pmc">PMC7483430</ArticleId><ArticleId IdType="pubmed">32573711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, P&#xe3;o CRR, et al. . Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood (2020) 136(11):1330&#x2013;41. doi:&#xa0;10.1182/blood.2020007252</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007252</ArticleId><ArticleId IdType="pmc">PMC7483437</ArticleId><ArticleId IdType="pubmed">32678428</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieuwdorp M, van Haeften TW, Gouverneur MC, Mooij HL, van Lieshout MH, Levi M, et al. . Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo . Diabetes (2006) 55(2):480&#x2013;6. doi:&#xa0;10.2337/diabetes.55.02.06.db05-1103</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.55.02.06.db05-1103</ArticleId><ArticleId IdType="pubmed">16443784</ArticleId></ArticleIdList></Reference><Reference><Citation>Noubouossie DF, Whelihan MF, Yu YB, Sparkenbaugh E, Pawlinski R, Monroe DM, et al. . In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. Blood (2017) 129(8):1021&#x2013;9. doi:&#xa0;10.1182/blood-2016-06-722298</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-06-722298</ArticleId><ArticleId IdType="pmc">PMC5324715</ArticleId><ArticleId IdType="pubmed">27919911</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanch-Ruiz MA, Ortega-Luna R, G&#xf3;mez-Garc&#xed;a G, Mart&#xed;nez-Cuesta M&#xc1;, &#xc1;lvarez &#xc1;. Role of neutrophil extracellular traps in COVID-19 progression: An insight for effective treatment. Biomedicines (2021) 10(1):31. doi:&#xa0;10.3390/biomedicines10010031</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10010031</ArticleId><ArticleId IdType="pmc">PMC8772933</ArticleId><ArticleId IdType="pubmed">35052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. . Neutrophil extracellular traps in COVID-19. JCI Insight (2020) 5(11):e138999. doi:&#xa0;10.1172/jci.insight.138999</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.138999</ArticleId><ArticleId IdType="pmc">PMC7308057</ArticleId><ArticleId IdType="pubmed">32329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Veras FP, Pontelli MC, Silva CM, Toller-Kawahisa JE, de Lima M, Nascimento DC, et al. . SARS-CoV-2-Triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med (2020) 217(12):e20201129. doi:&#xa0;10.1084/jem.20201129</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201129</ArticleId><ArticleId IdType="pmc">PMC7488868</ArticleId><ArticleId IdType="pubmed">32926098</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu&#xe9;ant JL, Fromonot J, Gu&#xe9;ant-Rodriguez RM, Lacolley P, Guieu R, Regnault V. Blood myeloperoxidase-DNA, a biomarker of early response to SARS-CoV-2 infection? Allergy (2021) 76(3):892&#x2013;6. doi:&#xa0;10.1111/all.14533</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14533</ArticleId><ArticleId IdType="pmc">PMC7436665</ArticleId><ArticleId IdType="pubmed">32743884</ArticleId></ArticleIdList></Reference><Reference><Citation>Schurink B, Roos E, Radonic T, Barbe E, Bouman CSC, de Boer HH, et al. . Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe (2020) 1(7):e290&#x2013;9. doi:&#xa0;10.1016/S2666-5247(20)30144-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30144-0</ArticleId><ArticleId IdType="pmc">PMC7518879</ArticleId><ArticleId IdType="pubmed">33015653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman N. Triggers, targets and treatments for thrombosis. Nature (2008) 451(7181):914&#x2013;8. doi:&#xa0;10.1038/nature06797</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06797</ArticleId><ArticleId IdType="pmc">PMC2848509</ArticleId><ArticleId IdType="pubmed">18288180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruf W. Role of thiol pathways in TF procoagulant regulation. Thromb Res (2012) 129 Suppl 2(Suppl 2):S11&#x2013;2. doi:&#xa0;10.1016/j.thromres.2012.02.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2012.02.020</ArticleId><ArticleId IdType="pmc">PMC3393083</ArticleId><ArticleId IdType="pubmed">22401798</ArticleId></ArticleIdList></Reference><Reference><Citation>Popescu NI, Lupu C, Lupu F. Extracellular protein disulfide isomerase regulates coagulation on endothelial cells through modulation of phosphatidylserine exposure. Blood (2010) 116(6):993&#x2013;1001. doi:&#xa0;10.1182/blood-2009-10-249607</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-10-249607</ArticleId><ArticleId IdType="pmc">PMC2924232</ArticleId><ArticleId IdType="pubmed">20448108</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann L, Rolling CC, Voigtl&#xe4;nder M, M&#xe4;der J, Klingler F, Schulenkorf A, et al. . Bacitracin and rutin regulate tissue factor production in inflammatory monocytes and acute myeloid leukemia blasts. Cancers (Basel) (2021) 13(16):3941. doi:&#xa0;10.3390/cancers13163941</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13163941</ArticleId><ArticleId IdType="pmc">PMC8393688</ArticleId><ArticleId IdType="pubmed">34439096</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappellano G, Raineri D, Rolla R, Giordano M, Puricelli C, Vilardo B, et al. . Circulating platelet-derived extracellular vesicles are a hallmark of sars-Cov-2 infection. Cells (2021) 10(1):85. doi:&#xa0;10.3390/cells10010085</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10010085</ArticleId><ArticleId IdType="pmc">PMC7825711</ArticleId><ArticleId IdType="pubmed">33430260</ArticleId></ArticleIdList></Reference><Reference><Citation>Garnier Y, Claude L, Hermand P, Sachou E, Claes A, Desplan K, et al. . Plasma microparticles of intubated COVID-19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine-dependent manner. Br J Haematol (2022) 196(5):1159&#x2013;69. doi:&#xa0;10.1111/bjh.18019</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.18019</ArticleId><ArticleId IdType="pubmed">34962643</ArticleId></ArticleIdList></Reference><Reference><Citation>Guervilly C, Bonifay A, Burtey S, Sabatier F, Cauchois R, Abdili E, et al. . Dissemination of extreme levels of extracellular vesicles: Tissue factor activity in patients with severe COVID-19. Blood Adv (2021) 5(3):628&#x2013;34. doi:&#xa0;10.1182/bloodadvances.2020003308</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003308</ArticleId><ArticleId IdType="pmc">PMC7846479</ArticleId><ArticleId IdType="pubmed">33560376</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton EA, He XY, Denorme F, Campbell RA, Ng D, Salvatore SP, et al. . Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood (2020) 136(10):1169&#x2013;79. doi:&#xa0;10.1182/blood.2020007008</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007008</ArticleId><ArticleId IdType="pmc">PMC7472714</ArticleId><ArticleId IdType="pubmed">32597954</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevers EM, Williamson PL. Getting to the outer leaflet: Physiology of phosphatidylserine exposure at the plasma membrane. Physiol Rev (2016) 96(2):605&#x2013;45. doi: 10.1152/physrev.00020.2015</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00020.2015</ArticleId><ArticleId IdType="pubmed">26936867</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin HW, Takatsu H. Phosphatidylserine exposure in living cells. Crit Rev Biochem Mol Biol (2020) 55(2):166&#x2013;78. doi:&#xa0;10.1080/10409238.2020.1758624</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10409238.2020.1758624</ArticleId><ArticleId IdType="pubmed">32408772</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Cheng X, Tang Y, Qiu X, Wang Y, Kang H, et al. . Bacterial endotoxin activates the coagulation cascade through gasdermin d-dependent phosphatidylserine exposure. Immunity (2019) 51(6):983&#x2013;996.e6. doi: 10.1016/j.immuni.2019.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.11.005</ArticleId><ArticleId IdType="pubmed">31836429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripisciano C, Weiss R, Karuthedom George S, Fischer MB, Weber V. Extracellular vesicles derived from platelets, red blood cells, and monocyte-like cells differ regarding their ability to induce factor XII-dependent thrombin generation. Front Cell Dev Biol (2020) 8:298. doi:&#xa0;10.3389/fcell.2020.00298</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00298</ArticleId><ArticleId IdType="pmc">PMC7232549</ArticleId><ArticleId IdType="pubmed">32478066</ArticleId></ArticleIdList></Reference><Reference><Citation>Millington-Burgess SL, Bonna AM, Rahman T, Harper MT. Ethaninidothioic acid (R5421) is not a selective inhibitor of platelet phospholipid scramblase activity. Br J Pharmacol (2020) 177(17):4007&#x2013;20. doi:&#xa0;10.1111/bph.15152</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15152</ArticleId><ArticleId IdType="pmc">PMC7429475</ArticleId><ArticleId IdType="pubmed">32496597</ArticleId></ArticleIdList></Reference><Reference><Citation>Rausch L, Lutz K, Schifferer M, Winheim E, Gruber R, Oesterhaus EF, et al. . Binding of phosphatidylserine-positive microparticles by PBMCs classifies disease severity in COVID-19 patients. J Extracell Vesicles (2021) 10(14):e12173. doi:&#xa0;10.1002/jev2.12173</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jev2.12173</ArticleId><ArticleId IdType="pmc">PMC8636722</ArticleId><ArticleId IdType="pubmed">34854246</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Yu C, Novakovic VA, Xie R, Shi J. Circulating microparticles in the pathogenesis and early anticoagulation of thrombosis in COVID-19 with kidney injury. Front Cell Dev Biol (2022) 9:784505. doi:&#xa0;10.3389/fcell.2021.784505</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.784505</ArticleId><ArticleId IdType="pmc">PMC8804312</ArticleId><ArticleId IdType="pubmed">35118071</ArticleId></ArticleIdList></Reference><Reference><Citation>Althaus K, Marini I, Zlamal J, Pelzl L, Singh A, H&#xe4;berle H, et al. . Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood (2021) 137(8):1061&#x2013;71. doi:&#xa0;10.1182/blood.2020008762</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008762</ArticleId><ArticleId IdType="pmc">PMC7791311</ArticleId><ArticleId IdType="pubmed">33512415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim EHT, van Amstel RBE, de Boer VV, van Vught LA, de Bruin S, Brouwer MC, et al. . Complement activation in COVID-19 and targeted therapeutic options: A scoping review. Blood Rev (2022) 100995. doi:&#xa0;10.1016/j.blre.2022.100995</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2022.100995</ArticleId><ArticleId IdType="pmc">PMC9338830</ArticleId><ArticleId IdType="pubmed">35934552</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim MS, Mcrae S. COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. Crit Rev Oncol Hematol (2021) 168:103529. doi:&#xa0;10.1016/j.critrevonc.2021.103529</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2021.103529</ArticleId><ArticleId IdType="pmc">PMC8596655</ArticleId><ArticleId IdType="pubmed">34800652</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmon CT. Inflammation and the activated protein c anticoagulant pathway. Semin Thromb Hemost (2006) 32 Suppl 1:49&#x2013;60. doi:&#xa0;10.1055/s-2006-939554</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2006-939554</ArticleId><ArticleId IdType="pubmed">16673266</ArticleId></ArticleIdList></Reference><Reference><Citation>Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, et al. . Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest (2020) 130(11):6151&#x2013;7. doi:&#xa0;10.1172/JCI141374</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI141374</ArticleId><ArticleId IdType="pmc">PMC7598040</ArticleId><ArticleId IdType="pubmed">32759504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem (1990) 265(7):3809&#x2013;14. doi: 10.1016/S0021-9258(19)39666-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)39666-8</ArticleId><ArticleId IdType="pubmed">2105954</ArticleId></ArticleIdList></Reference><Reference><Citation>Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: Implications for vascular inflammation and thrombosis. Mol Immunol (2010) 47(13):2170&#x2013;5. doi:&#xa0;10.1016/j.molimm.2010.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2010.05.009</ArticleId><ArticleId IdType="pmc">PMC2904326</ArticleId><ArticleId IdType="pubmed">20621693</ArticleId></ArticleIdList></Reference><Reference><Citation>Polley MJ, Nachman R. The human complement system in thrombin-mediated platelet function. J Exp Med (1978) 147(6):1713&#x2013;26. doi:&#xa0;10.1084/jem.147.6.1713</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.147.6.1713</ArticleId><ArticleId IdType="pmc">PMC2184322</ArticleId><ArticleId IdType="pubmed">681879</ArticleId></ArticleIdList></Reference><Reference><Citation>Verschoor A, Neuenhahn M, Navarini AA, Graef P, Plaumann A, Seidlmeier A, et al. . A platelet-mediated system for shuttling blood-borne bacteria to CD8&#x3b1;+ dendritic cells depends on glycoprotein GPIb and complement C3. Nat Immunol (2011) 12(12):1194&#x2013;201. doi:&#xa0;10.1038/ni.2140</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2140</ArticleId><ArticleId IdType="pubmed">22037602</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. . Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res (2020) 220:1&#x2013;13. doi:&#xa0;10.1016/j.trsl.2020.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2020.04.007</ArticleId><ArticleId IdType="pmc">PMC7158248</ArticleId><ArticleId IdType="pubmed">32299776</ArticleId></ArticleIdList></Reference><Reference><Citation>Della-Morte D, Pacifici F, Ricordi C, Massoud R, Rovella V, Proietti S, et al. . Low level of plasminogen increases risk for mortality in COVID-19 patients. Cell Death Dis (2021) 12(8):773. doi:&#xa0;10.1038/s41419-021-04070-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-04070-3</ArticleId><ArticleId IdType="pmc">PMC8340078</ArticleId><ArticleId IdType="pubmed">34354045</ArticleId></ArticleIdList></Reference><Reference><Citation>Gacche RN, Gacche RA, Chen J, Li H, Li G. Predictors of morbidity and mortality in COVID-19. Eur Rev Med Pharmacol Sci (2021) 25(3):1684&#x2013;707. doi:&#xa0;10.26355/eurrev_202102_24880</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202102_24880</ArticleId><ArticleId IdType="pubmed">33629339</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachler M, B&#xf6;sch J, St&#xfc;rzel DP, Hell T, Giebl A, Str&#xf6;hle M, et al. . Impaired fibrinolysis in critically ill COVID-19 patients. Br J Anaesth (2021) 126(3):590&#x2013;8. doi:&#xa0;10.1016/j.bja.2020.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bja.2020.12.010</ArticleId><ArticleId IdType="pmc">PMC7833514</ArticleId><ArticleId IdType="pubmed">33422287</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, et al. . Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood (2010) 116(1):113&#x2013;21. doi:&#xa0;10.1182/blood-2010-02-267740</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-02-267740</ArticleId><ArticleId IdType="pubmed">20385790</ArticleId></ArticleIdList></Reference><Reference><Citation>Susen S, Tacquard CA, Godon A, Mansour A, Garrigue D, Nguyen P, et al. . Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Crit Care (2020) 24(1):364. doi:&#xa0;10.1186/s13054-020-03000-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03000-7</ArticleId><ArticleId IdType="pmc">PMC7303590</ArticleId><ArticleId IdType="pubmed">32560658</ArticleId></ArticleIdList></Reference><Reference><Citation>Heuberger DM, Schuepbach RA. Protease-activated receptors (PARs): Mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb J (2019) 17:4. doi:&#xa0;10.1186/s12959-019-0194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-019-0194-8</ArticleId><ArticleId IdType="pmc">PMC6440139</ArticleId><ArticleId IdType="pubmed">30976204</ArticleId></ArticleIdList></Reference><Reference><Citation>Tull SP, Bevins A, Kuravi SJ, Satchell SC, Al-Ani B, Young SP, et al. . PR3 and elastase alter PAR1 signaling and trigger vWF release via a calcium-independent mechanism from glomerular endothelial cells. PloS One (2012) 7(8):e43916. doi:&#xa0;10.1371/journal.pone.0043916</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0043916</ArticleId><ArticleId IdType="pmc">PMC3430624</ArticleId><ArticleId IdType="pubmed">22952809</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, et al. . Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood (2004) 103(6):2096&#x2013;104. doi:&#xa0;10.1182/blood-2003-08-2804</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2003-08-2804</ArticleId><ArticleId IdType="pubmed">14630798</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci U.S.A. (1999) 96(20):11023&#x2013;7. doi:&#xa0;10.1073/pnas.96.20.11023</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.20.11023</ArticleId><ArticleId IdType="pmc">PMC34235</ArticleId><ArticleId IdType="pubmed">10500117</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan ZS, Zarpellon A, Alwis I, Yuan Y, McFadyen J, Ghasemzadeh M, et al. . Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4. Nat Commun (2015) 6:7835. doi:&#xa0;10.1038/ncomms8835</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8835</ArticleId><ArticleId IdType="pubmed">26204458</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch MH, Timmermans SAMEG, Nagy M, Visser M, Huckriede J, Aendekerk JP, et al. . Neutrophils and contact activation of coagulation as potential drivers of COVID-19. Circulation (2020) 142(18):1787&#x2013;90. doi:&#xa0;10.1161/CIRCULATIONAHA.120.050656</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.050656</ArticleId><ArticleId IdType="pmc">PMC7594534</ArticleId><ArticleId IdType="pubmed">32946302</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiech M, Chroscicki P, Swatler J, Stepnik D, De Biasi S, Hampel M, et al. . Remodeling of T cell dynamics during long COVID is dependent on severity of SARS-CoV-2 infection. Front Immunol (2022) 13:886431. doi:&#xa0;10.3389/fimmu.2022.886431</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.886431</ArticleId><ArticleId IdType="pmc">PMC9226563</ArticleId><ArticleId IdType="pubmed">35757700</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. . Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med (2022) 28(8):1706&#x2013;14. doi:&#xa0;10.1038/s41591-022-01909-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasannan N, Heightman M, Hillman T, Wall E, Bell R, Kessler A, et al. . Impaired exercise capacity in post-COVID-19 syndrome: the role of VWF-ADAMTS13 axis. Blood Adv (2022) 6(13):4041&#x2013;8. doi:&#xa0;10.1182/bloodadvances</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances</ArticleId><ArticleId IdType="pmc">PMC9098525</ArticleId><ArticleId IdType="pubmed">35543533</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. . Attributes and predictors of long COVID. Nat Med (2021) 27(4):626&#x2013;31. doi:&#xa0;10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KG, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, et al. . Long COVID in a prospective cohort of home-isolated patients. Nat Med (2021) 27(9):1607&#x2013;13. doi:&#xa0;10.1038/s41591-021-01433-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Honigsbaum M, Krishnan L. Taking pandemic sequelae seriously: from the Russian influenza to COVID-19 long-haulers. Lancet (2020) 396(10260):1389&#x2013;91. doi:&#xa0;10.1016/S0140-6736(20)32134-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32134-6</ArticleId><ArticleId IdType="pmc">PMC7550169</ArticleId><ArticleId IdType="pubmed">33058777</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (2021) 397(10270):220&#x2013;32. doi:&#xa0;10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Heesakkers H, van der Hoeven JG, Corsten S, Janssen I, Ewalds E, Simons KS, et al. . Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. JAMA (2022) 327(6):559&#x2013;65. doi:&#xa0;10.1001/jama.2022.0040</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.0040</ArticleId><ArticleId IdType="pmc">PMC8787680</ArticleId><ArticleId IdType="pubmed">35072716</ArticleId></ArticleIdList></Reference><Reference><Citation>Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC, et al. . Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood (2020) 136(11):1342&#x2013;6. doi:&#xa0;10.1182/blood.2020007938</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007938</ArticleId><ArticleId IdType="pmc">PMC7483433</ArticleId><ArticleId IdType="pubmed">32766883</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelen MM, Vandenbriele C, Balthazar T, Claeys E, Gunst J, Guler I, et al. . Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost (2021) 47(4):362&#x2013;71. doi:&#xa0;10.1055/s-0041-1727284</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1727284</ArticleId><ArticleId IdType="pubmed">33893631</ArticleId></ArticleIdList></Reference><Reference><Citation>Montani D, Savale L, Noel N, Meyrignac O, Colle R, Gasnier M, et al. . Post-acute COVID-19 syndrome. Eur Respir Rev (2022) 31(163):210185. doi:&#xa0;10.1183/16000617.0185-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0185-2021</ArticleId><ArticleId IdType="pmc">PMC8924706</ArticleId><ArticleId IdType="pubmed">35264409</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun (2022) 103:154&#x2013;62. doi:&#xa0;10.1016/j.bbi.2022.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.04.013</ArticleId><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt AA, Nafady-Hego H, Chemaitelly H, Abou-Samra AB, Khal AA, Coyle PV, et al. . Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination. Int J Infect Dis (2021) 110:353&#x2013;8. doi:&#xa0;10.1016/j.ijid.2021.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.08.008</ArticleId><ArticleId IdType="pmc">PMC8349447</ArticleId><ArticleId IdType="pubmed">34375762</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med (2022) 28(7):1461&#x2013;7. doi:&#xa0;10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Flemming A. Vaccines only partially protect against long COVID. Nat Rev Immunol (2022) 22(7):410. doi:&#xa0;10.1038/s41577-022-00749-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00749-6</ArticleId><ArticleId IdType="pmc">PMC9186276</ArticleId><ArticleId IdType="pubmed">35688881</ArticleId></ArticleIdList></Reference><Reference><Citation>Newell KL, Waickman AT. Inflammation, immunity, and antigen persistence in post-acute sequelae of SARS-CoV-2 infectionimmunity and inflammaion in post-acute sequelae of SARS-CoV-2 infection. Curr Opin Immunol (2022) 77:102228. doi:&#xa0;10.1016/j.coi.2022.102228</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2022.102228</ArticleId><ArticleId IdType="pmc">PMC9127180</ArticleId><ArticleId IdType="pubmed">35724449</ArticleId></ArticleIdList></Reference><Reference><Citation>Leppkes M, Neurath MF. Rear window-what can the gut tell us about long-COVID? Gastroenterology (2022) 163(2):376&#x2013;8. doi:&#xa0;10.1053/j.gastro.2022.05.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.05.044</ArticleId><ArticleId IdType="pmc">PMC9175081</ArticleId><ArticleId IdType="pubmed">35660031</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzin-Frankel J. Clues to long COVID. Science (2022) 376(6599):1261&#x2013;5. doi:&#xa0;10.1126/science.add4297</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.add4297</ArticleId><ArticleId IdType="pubmed">35709281</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. Can drugs reduce the risk of long COVID? what scientists know so far. Nature (2022) 604(7904):20&#x2013;1. doi:&#xa0;10.1038/d41586-022-00823-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-00823-y</ArticleId><ArticleId IdType="pubmed">35338366</ArticleId></ArticleIdList></Reference><Reference><Citation>Colmenero I, Santonja C, Alonso-Ria&#xf1;o M, Noguera-Morel L, Hern&#xe1;ndez-Mart&#xed;n A, Andina D, et al. . SARS-CoV-2 endothelial infection causes COVID-19 chilblains: Histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. Br J Dermatol (2020) 183(4):729&#x2013;37. doi:&#xa0;10.1111/bjd.19327</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.19327</ArticleId><ArticleId IdType="pmc">PMC7323219</ArticleId><ArticleId IdType="pubmed">32562567</ArticleId></ArticleIdList></Reference><Reference><Citation>Khider L, Gendron N, Goudot G, Chocron R, Hauw-Berlemont C, Cheng C, et al. . Curative anticoagulation prevents endothelial lesion in COVID-19 patients. J Thromb Haemost (2020) 18(9):2391&#x2013;9. doi:&#xa0;10.1111/jth.14968</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14968</ArticleId><ArticleId IdType="pmc">PMC7323356</ArticleId><ArticleId IdType="pubmed">32558198</ArticleId></ArticleIdList></Reference><Reference><Citation>Gy&#xf6;ngy&#xf6;si M, Alcaide P, Asselbergs FW, Brundel BJJM, Camici GG, da Costa Martins P, et al. . Long COVID and the cardiovascular system - elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: A joint scientific statement of the ESC working groups on cellular biology of the heart and myocardial &amp; pericardial diseases. Cardiovasc Res (2022). doi:&#xa0;10.1093/cvr/cvac115</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvac115</ArticleId><ArticleId IdType="pmc">PMC9384470</ArticleId><ArticleId IdType="pubmed">35875883</ArticleId></ArticleIdList></Reference><Reference><Citation>Targosz-Korecka M, Kubisiak A, Kloska D, Kopacz A, Grochot-Przeczek A, Szymonski M. Endothelial glycocalyx shields the interaction of SARS-CoV-2 spike protein with ACE2 receptors. Sci Rep (2021) 11(1):12157. doi:&#xa0;10.1038/s41598-021-91231-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-91231-1</ArticleId><ArticleId IdType="pmc">PMC8190434</ArticleId><ArticleId IdType="pubmed">34108510</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad M, Leon M, Lerman LO, Lerman A. Viral endothelial dysfunction: A unifying mechanism for COVID-19. Mayo Clin Proc (2021) 96(12):3099&#x2013;108. doi:&#xa0;10.1016/j.mayocp.2021.06.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2021.06.027</ArticleId><ArticleId IdType="pmc">PMC8373818</ArticleId><ArticleId IdType="pubmed">34863398</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lorenzo A, Escobar S, Tibiri&#xe7;&#xe1; E. Systemic endothelial dysfunction: A common pathway for COVID-19, cardiovascular and metabolic diseases. Nutr Metab Cardiovasc Dis (2020) 30(8):1401&#x2013;2. doi:&#xa0;10.1016/j.numecd.2020.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2020.05.007</ArticleId><ArticleId IdType="pmc">PMC7233254</ArticleId><ArticleId IdType="pubmed">32425360</ArticleId></ArticleIdList></Reference><Reference><Citation>Escher R, Breakey N, L&#xe4;mmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res (2020) 190:62. doi:&#xa0;10.1016/j.thromres.2020.04.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.04.014</ArticleId><ArticleId IdType="pmc">PMC7156948</ArticleId><ArticleId IdType="pubmed">32305740</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong SM, Darwish I, Lee WL. Endothelial activation and dysfunction in the pathogenesis of influenza a virus infection. Virulence (2013) 4(6):537&#x2013;42. doi:&#xa0;10.4161/viru.25779</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/viru.25779</ArticleId><ArticleId IdType="pmc">PMC5359731</ArticleId><ArticleId IdType="pubmed">23863601</ArticleId></ArticleIdList></Reference><Reference><Citation>Krautkr&#xe4;mer E, Zeier M, Plyusnin A. Hantavirus infection: an emerging infectious disease causing acute renal failure. Kidney Int (2013) 83(1):23&#x2013;7. doi:&#xa0;10.1038/ki.2012.360</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2012.360</ArticleId><ArticleId IdType="pubmed">23151954</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans PC, Rainger GE, Mason JC, Guzik TJ, Osto E, Stamataki Z, et al. . Endothelial dysfunction in COVID-19: a position paper of the ESC working group for atherosclerosis and vascular biology, and the ESC council of basic cardiovascular science. Cardiovasc Res (2020) 116(14):2177&#x2013;84. doi:&#xa0;10.1093/cvr/cvaa230</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvaa230</ArticleId><ArticleId IdType="pmc">PMC7454368</ArticleId><ArticleId IdType="pubmed">32750108</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med (2022) 28(3):583&#x2013;90. doi:&#xa0;10.1038/s41591-022-01689-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo R, Trimarco V, Mone P, Alo&#xe8; T, MC M, Diana A, et al. . Combining l-arginine with vitamin c improves long-COVID symptoms: The nationwide multicenter LINCOLN study. Pharmacol Res (2022) 106360. doi:&#xa0;10.1016/j.phrs.2022.106360</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2022.106360</ArticleId><ArticleId IdType="pmc">PMC9295384</ArticleId><ArticleId IdType="pubmed">35868478</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikonomou E, Souvaliotis N, Lampsas S, Siasos G, Poulakou G, Theofilis P, et al. . Endothelial dysfunction in acute and long standing COVID-19: A prospective cohort study. Vascul Pharmacol (2022) 144:106975. doi:&#xa0;10.1016/j.vph.2022.106975</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vph.2022.106975</ArticleId><ArticleId IdType="pmc">PMC8893931</ArticleId><ArticleId IdType="pubmed">35248780</ArticleId></ArticleIdList></Reference><Reference><Citation>Chioh FW, Fong SW, Young BE, Wu KX, Siau A, Krishnan S, et al. . Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. Elife (2021) 10:e64909. doi:&#xa0;10.7554/eLife.64909</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.64909</ArticleId><ArticleId IdType="pmc">PMC7987341</ArticleId><ArticleId IdType="pubmed">33752798</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, Ahmad A, Comerford C, Karampini E, et al. . Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost (2021) 19(10):2546&#x2013;53. doi:&#xa0;10.1111/jth.15490</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia-Renteria H, Travieso A, Sagir A, Mart&#xed;nez-G&#xf3;mez E, Carrascosa-Granada A, Toya T, et al. . In-vivo evidence of systemic endothelial vascular dysfunction in COVID-19. Int J Cardiol (2021) 345:153&#x2013;5. doi:&#xa0;10.1016/j.ijcard.2021.10.140</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2021.10.140</ArticleId><ArticleId IdType="pmc">PMC8542397</ArticleId><ArticleId IdType="pubmed">34706286</ArticleId></ArticleIdList></Reference><Reference><Citation>Szeghy RE, Province VM, Stute NL, Augenreich MA, Koontz LK, Stickford JL, et al. . Carotid stiffness, intima-media thickness and aortic augmentation index among adults with SARS-CoV-2. Exp Physiol (2022) 107(7):694&#x2013;707. doi:&#xa0;10.1113/EP089481</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/EP089481</ArticleId><ArticleId IdType="pmc">PMC8239784</ArticleId><ArticleId IdType="pubmed">33904234</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaitzsch E, Czermak T, Ribeiro A, Heun Y, Bohmer M, Merkle M, et al. . Double-stranded DNA induces a prothrombotic phenotype in the vascular endothelium. Sci Rep (2017) 7(1):1112. doi:&#xa0;10.1038/s41598-017-01148-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-01148-x</ArticleId><ArticleId IdType="pmc">PMC5430798</ArticleId><ArticleId IdType="pubmed">28442771</ArticleId></ArticleIdList></Reference><Reference><Citation>Loscalzo J. Oxidative stress in endothelial cell dysfunction and thrombosis. Pathophysiol Haemost Thromb (2002) 32(5-6):359&#x2013;60. doi:&#xa0;10.1159/000073600</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000073600</ArticleId><ArticleId IdType="pubmed">13679676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakar P, Lip GY. Hypertension: Endothelial dysfunction, the prothrombotic state and antithrombotic therapy. Expert Rev Cardiovasc Ther (2007) 5(3):441&#x2013;50. doi:&#xa0;10.1586/14779072.5.3.441</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14779072.5.3.441</ArticleId><ArticleId IdType="pubmed">17489669</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Fogarty H, Dyer A, Martin-Loeches I, Bannan C, Nadarajan P, et al. . Prolonged elevation of d-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J Thromb Haemost (2021) 19(4):1064&#x2013;70. doi:&#xa0;10.1111/jth.15267</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15267</ArticleId><ArticleId IdType="pmc">PMC8013297</ArticleId><ArticleId IdType="pubmed">33587810</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan BE, Wong SW, Sum CLL, Lim GH, Leung BP, Tan CW, et al. . Hypercoagulability, endotheliopathy, and inflammation approximating 1&#x2009;year after recovery: Assessing the long-term outcomes in COVID-19 patients. Am J Hematol (2022) 97(7):915&#x2013;23. doi:&#xa0;10.1002/ajh.26575</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26575</ArticleId><ArticleId IdType="pmc">PMC9073976</ArticleId><ArticleId IdType="pubmed">35477923</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Ward SE, Townsend L, Karampini E, Elliott S, Conlon N, et al. . Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. J Thromb Haemost (2022) 20(10):2429&#x2013;38. doi:&#xa0;10.1111/jth.15830</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15830</ArticleId><ArticleId IdType="pmc">PMC9349977</ArticleId><ArticleId IdType="pubmed">35875995</ArticleId></ArticleIdList></Reference><Reference><Citation>Petito E, Falcinelli E, Paliani U, Cesari E, Vaudo G, Sebastiano M, et al. . Association of neutrophil activation, more than platelet activation, with thrombotic complications in coronavirus disease 2019. J Infect Dis (2021) 223(6):933&#x2013;44. doi:&#xa0;10.1093/infdis/jiaa756</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa756</ArticleId><ArticleId IdType="pmc">PMC7798977</ArticleId><ArticleId IdType="pubmed">33280009</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Nishikawa M, Kanno H, Yang R, Ibayashi Y, Xiao TH, et al. . Long-term effects of pfizer-BioNTech COVID-19 vaccinations on platelets. Cytometry A (2022). doi:&#xa0;10.1002/cyto.a.24677</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.24677</ArticleId><ArticleId IdType="pmc">PMC9538905</ArticleId><ArticleId IdType="pubmed">35938513</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Chen X, Liu X. NETosis and neutrophil extracellular traps in COVID-19: Immunothrombosis and beyond. Front Immunol (2022) 13:838011. doi:&#xa0;10.3389/fimmu.2022.838011</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.838011</ArticleId><ArticleId IdType="pmc">PMC8924116</ArticleId><ArticleId IdType="pubmed">35309344</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou M, Yuan D, Liao S, Tong L, Li J. Potential mechanisms of cerebrovascular diseases in COVID-19 patients. J Neurovirol (2021) 27(1):35&#x2013;51. doi:&#xa0;10.1007/s13365-021-00948-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-00948-2</ArticleId><ArticleId IdType="pmc">PMC7856859</ArticleId><ArticleId IdType="pubmed">33534131</ArticleId></ArticleIdList></Reference><Reference><Citation>Dryden M, Mudara C, Vika C, Blumberg L, Mayet N, Cohen C, et al. . Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in south Africa: A prospective cohort study. Lancet Glob Health (2022) 10(9):e1247&#x2013;56. doi:&#xa0;10.1016/S2214-109X(22)00286-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00286-8</ArticleId><ArticleId IdType="pmc">PMC9363040</ArticleId><ArticleId IdType="pubmed">35961348</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cleemput J, van Snippenberg W, Lambrechts L, Dendooven A, D'Onofrio V, Couck L, et al. . Organ-specific genome diversity of replication-competent SARS-CoV-2. Nat Commun (2021) 12(1):6612. doi:&#xa0;10.1038/s41467-021-26884-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26884-7</ArticleId><ArticleId IdType="pmc">PMC8595628</ArticleId><ArticleId IdType="pubmed">34785663</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. . Evolution of antibody immunity to SARS-CoV-2. Nature (2021) 591(7851):639&#x2013;44. doi:&#xa0;10.1038/s41586-021-03207-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Laing AG, Lorenc A, Del Molino Del Barrio I, Das A, Fish M, Monin L, et al. . A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med (2020) 26(10):1623&#x2013;35. doi:&#xa0;10.1038/s41591-020-1038-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1038-6</ArticleId><ArticleId IdType="pubmed">32807934</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. . More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep (2021) 11(1):16144. doi:&#xa0;10.1038/s41598-021-95565-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodr&#xed;guez Y, Zapata E, Ram&#xed;rez-Santana C, et al. . Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis (2022) 225(12):2155&#x2013;62. doi:&#xa0;10.1093/infdis/jiac017</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripani U, Bisaccia M, Meccariello L. Dexamethasone and nutraceutical therapy can reduce the myalgia due to COVID-19 - a systemic review of the active substances that can reduce the expression of interlukin-6. Med Arch (2022) 76(1):66&#x2013;71. doi:&#xa0;10.5455/medarh.2022.76.66-71</Citation><ArticleIdList><ArticleId IdType="doi">10.5455/medarh.2022.76.66-71</ArticleId><ArticleId IdType="pmc">PMC8976893</ArticleId><ArticleId IdType="pubmed">35422571</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz MAF, Neves PFMD, Lima SS, Lopes JDC, Torres MKDS, Vallinoto IMVC, et al. . Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome. Front Cell Infect Microbiol (2022) 12:922422. doi:&#xa0;10.3389/fcimb.2022.922422</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuwa HA, Shaw TN, Knight SB, Wemyss K, McClure FA, Pearmain L, et al. . Alterations in T and b cell function persist in convalescent COVID-19 patients. Med (NY) (2021) 2(6):720&#x2013;735.e4. doi:&#xa0;10.1016/j.medj.2021.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.03.013</ArticleId><ArticleId IdType="pmc">PMC8011689</ArticleId><ArticleId IdType="pubmed">33821250</ArticleId></ArticleIdList></Reference><Reference><Citation>Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J, et al. . Increased memory b cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature (2022) 607(7917):128&#x2013;34. doi:&#xa0;10.1038/s41586-022-04778-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04778-y</ArticleId><ArticleId IdType="pmc">PMC9259484</ArticleId><ArticleId IdType="pubmed">35447027</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitre T, Van Alstine R, Chick G, Leung G, Mikhail D, Cusano E, et al. . Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis. CMAJ (2022) 194(28):E969&#x2013;80. doi:&#xa0;10.1503/cmaj.220471</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.220471</ArticleId><ArticleId IdType="pmc">PMC9328465</ArticleId><ArticleId IdType="pubmed">35878897</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccicacco N, Zeitler K, Ing A, Montero J, Faughn J, Silbert S, et al. . Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the omicron surge. J Antimicrob Chemother (2022) 77(10):2693&#x2013;700. doi:&#xa0;10.1093/jac/dkac256</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkac256</ArticleId><ArticleId IdType="pmc">PMC9384598</ArticleId><ArticleId IdType="pubmed">35913836</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao K, Tzou PL, Kosakovsky Pond SL, Ioannidis JPA, Shafer RW. Susceptibility of SARS-CoV-2 omicron variants to therapeutic monoclonal antibodies: Systematic review and meta-analysis. Microbiol Spectr (2022) 10(4):e0092622. doi:&#xa0;10.1128/spectrum.00926-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.00926-22</ArticleId><ArticleId IdType="pmc">PMC9430471</ArticleId><ArticleId IdType="pubmed">35700134</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DT, McCreary EK, Bariola JR, Minnier TE, Wadas RJ, Shovel JA, et al. . Effectiveness of casirivimab-imdevimab and sotrovimab during a SARS-CoV-2 delta variant surge: A cohort study and randomized comparative effectiveness trial. JAMA Netw Open (2022) 5(7):e2220957. doi:&#xa0;10.1001/jamanetworkopen</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen</ArticleId><ArticleId IdType="pmc">PMC10881222</ArticleId><ArticleId IdType="pubmed">35834252</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch C, Park YS, Piechotta V, Chai KL, Estcourt LJ, Monsef I, et al. . SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database Syst Rev (2022) 6(6):CD014945. doi:&#xa0;10.1002/14651858</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858</ArticleId><ArticleId IdType="pmc">PMC9205158</ArticleId><ArticleId IdType="pubmed">35713300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes RD, de Barros E Silva PGM, Furtado RHM, Macedo AVS, Bronhara B, Damiani LP, et al. . Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated d-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet (2021) 397(10291):2253&#x2013;63. doi:&#xa0;10.1016/S0140-6736(21)01203-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01203-4</ArticleId><ArticleId IdType="pmc">PMC8177770</ArticleId><ArticleId IdType="pubmed">34097856</ArticleId></ArticleIdList></Reference><Reference><Citation>REMAP-CAP Investigators. ACTIV-4a Investigators. ATTACC Investigators. Goligher EC, Bradbury CA, McVerry BJ, et al. . ;Therapeutic anticoagulation with heparin in critically ill patients with covid-19. N Engl J Med (2021) 385(9):777&#x2013;89. doi:&#xa0;10.1056/NEJMoa2103417</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103417</ArticleId><ArticleId IdType="pmc">PMC8362592</ArticleId><ArticleId IdType="pubmed">34351722</ArticleId></ArticleIdList></Reference><Reference><Citation>ATTACC Investigators. ACTIV-4a Investigators. REMAP-CAP Investigators. Lawler PR, Goligher EC, Berger JS, et al. . ;Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19. N Engl J Med (2021) 385(9):790&#x2013;802. doi:&#xa0;10.1056/NEJMoa2105911</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105911</ArticleId><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrar JE, Trujillo TC, Mueller SW, Beltran L, Nguyen C, Hassell K, et al. . Evaluation of a patient specific, targeted-intensity pharmacologic thromboprophylaxis protocol in hospitalized patients with COVID-19. J Thromb Thrombolysis (2022) 53(2):446&#x2013;53. doi:&#xa0;10.1007/s11239-021-02552-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02552-x</ArticleId><ArticleId IdType="pmc">PMC8375286</ArticleId><ArticleId IdType="pubmed">34410561</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadkarni GN, Lala A, Bagiella E, Chang HL, Moreno PR, Pujadas E, et al. . Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol (2020) 76(16):1815&#x2013;26. doi: 10.1016/j.jacc.2020.08.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.08.041</ArticleId><ArticleId IdType="pmc">PMC7449655</ArticleId><ArticleId IdType="pubmed">32860872</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogenboom WS, Lu JQ, Musheyev B, Borg L, Janowicz R, Pamlayne S, et al. . Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19. PloS One (2022) 17(1):e0262811. doi:&#xa0;10.1371/journal.pone.0262811</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262811</ArticleId><ArticleId IdType="pmc">PMC8769345</ArticleId><ArticleId IdType="pubmed">35045130</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita Y, Yachi S, Takeyama M, Nishimoto Y, Tsujino I, Nakamura J, et al. . Therapeutic-dose vs. prophylactic-dose anticoagulation therapy for critically ill patients with COVID-19 in a practice-based observational study. Circ J (2022) 86(7):1137&#x2013;42. doi:&#xa0;10.1253/circj.CJ-22-0209</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-22-0209</ArticleId><ArticleId IdType="pubmed">35662177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofia R, Carbone M, Landoni G, Zangrillo A, Dagna L. Anticoagulation as secondary prevention of massive lung thromboses in hospitalized patients with COVID-19. Eur J Intern Med (2022) 100:21&#x2013;4. doi:&#xa0;10.1016/j.ejim.2022.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2022.04.009</ArticleId><ArticleId IdType="pmc">PMC9005384</ArticleId><ArticleId IdType="pubmed">35487806</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, et al. . Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: The HEP-COVID randomized clinical trial. JAMA Intern Med (2021) 181(12):1612&#x2013;20. doi:&#xa0;10.1001/jamainternmed.2021.6203</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.6203</ArticleId><ArticleId IdType="pmc">PMC8498934</ArticleId><ArticleId IdType="pubmed">34617959</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramacciotti E, Barile Agati L, Calderaro D, Aguiar VCR, Spyropoulos AC, de Oliveira CCC, et al. . Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet (2022) 399(10319):50&#x2013;9. doi:&#xa0;10.1016/S0140-6736(21)02392-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02392-8</ArticleId><ArticleId IdType="pmc">PMC8673881</ArticleId><ArticleId IdType="pubmed">34921756</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, et al. . American Society of hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Adv (2021) 5(20):3951&#x2013;9. doi:&#xa0;10.1182/bloodadvances.2021005493</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021005493</ArticleId><ArticleId IdType="pmc">PMC8416320</ArticleId><ArticleId IdType="pubmed">34474482</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragkou PC, Palaiodimou L, Stefanou MI, Katsanos AH, Lambadiari V, Paraskevis D, et al. . Effects of low molecular weight heparin and fondaparinux on mortality, hemorrhagic and thrombotic complications in COVID-19 patients. Ther Adv Neurol Disord (2022) 15:17562864221099472. doi:&#xa0;10.1177/17562864221099472</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17562864221099472</ArticleId><ArticleId IdType="pmc">PMC9136435</ArticleId><ArticleId IdType="pubmed">35646159</ArticleId></ArticleIdList></Reference><Reference><Citation>Leentjens J, van Haaps TF, Wessels PF, Schutgens REG, Middeldorp S. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol (2021) 8(7):e524&#x2013;33. doi:&#xa0;10.1016/S2352-3026(21)00105-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(21)00105-8</ArticleId><ArticleId IdType="pmc">PMC8078884</ArticleId><ArticleId IdType="pubmed">33930350</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong L, Chen G, Cai Z, Liu H, Zhang C, Wang F, et al. . Balancing microthrombosis and inflammation via injectable protein hydrogel for inflammatory bowel disease. Adv Sci (Weinh) (2022) 9(20):e2200281. doi:&#xa0;10.1002/advs.202200281</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202200281</ArticleId><ArticleId IdType="pmc">PMC9284187</ArticleId><ArticleId IdType="pubmed">35524641</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel B, Rashid J, Gupta N, Ahsan F. Low-Molecular-Weight heparin-coated and montelukast-filled inhalable particles: A dual-drug delivery system for combination therapy in asthma. J Pharm Sci (2017) 106(4):1124&#x2013;35. doi:&#xa0;10.1016/j.xphs.2016.12.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2016.12.025</ArticleId><ArticleId IdType="pubmed">28057540</ArticleId></ArticleIdList></Reference><Reference><Citation>McFadyen JD, Stevens H, Peter K. The emerging threat of (Micro) thrombosis in COVID-19 and its therapeutic implications. Circ Res (2020) 127(4):571&#x2013;87. doi:&#xa0;10.1161/CIRCRESAHA.120.317447</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317447</ArticleId><ArticleId IdType="pmc">PMC7386875</ArticleId><ArticleId IdType="pubmed">32586214</ArticleId></ArticleIdList></Reference><Reference><Citation>Renn&#xe9; T, Stavrou EX. Roles of factor XII in innate immunity. Front Immunol (2019) 10:2011. doi:&#xa0;10.3389/fimmu.2019.02011</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02011</ArticleId><ArticleId IdType="pmc">PMC6713930</ArticleId><ArticleId IdType="pubmed">31507606</ArticleId></ArticleIdList></Reference><Reference><Citation>Mailer RK, Rangaswamy C, Konrath S, Emsley J, Renn&#xe9; T. An update on factor XII-driven vascular inflammation. Biochim Biophys Acta Mol Cell Res (2022) 1869(1):119166. doi:&#xa0;10.1016/j.bbamcr.2021.119166</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2021.119166</ArticleId><ArticleId IdType="pubmed">34699874</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelboom J, Floege J, Thadhani R, Weitz JI, Winkelmayer WC. Anticoagulation in patients with kidney failure on dialysis: Factor XI as a therapeutic target. Kidney Int (2021) 100(6):1199&#x2013;207. doi:&#xa0;10.1016/j.kint.2021.08.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.08.028</ArticleId><ArticleId IdType="pubmed">34600964</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopp S, Kraemmer D, Ay C. Factor XI inhibitors for prevention and treatment of venous thromboembolism: A review on the rationale and update on current evidence. Front Cardiovasc Med (2022) 9:903029. doi:&#xa0;10.3389/fcvm.2022.903029</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.903029</ArticleId><ArticleId IdType="pmc">PMC9133368</ArticleId><ArticleId IdType="pubmed">35647061</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. . Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med (2017) 377(14):1319&#x2013;30. doi:&#xa0;10.1056/NEJMoa1709118</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1709118</ArticleId><ArticleId IdType="pubmed">28844192</ArticleId></ArticleIdList></Reference><Reference><Citation>Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK, et al. . Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. Circulation (2019) 140(7):529&#x2013;37. doi:&#xa0;10.1161/CIRCULATIONAHA.119.039609</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.119.039609</ArticleId><ArticleId IdType="pmc">PMC6693980</ArticleId><ArticleId IdType="pubmed">31163978</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhof P, Ezekowitz MD, Purmah Y, Schiffer S, Meng IL, Camm AJ, et al. . Effects of rivaroxaban on biomarkers of coagulation and inflammation: A Post hoc analysis of the X-VeRT trial. TH Open (2020) 4(1):e20&#x2013;32. doi:&#xa0;10.1055/s-0040-1701206</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1701206</ArticleId><ArticleId IdType="pmc">PMC6978177</ArticleId><ArticleId IdType="pubmed">31984306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes RD, de Barros E Silva PGM, Furtado RHM, Macedo AVS, Ramacciotti E, Damini LP, et al. . Randomized clinical trial to evaluate a routine full anticoagulation strategy in patients with coronavirus infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (Anticoagulation coronavirus)-coalition IV trial. Am Heart J (2021) 238:1&#x2013;11. doi:&#xa0;10.1016/j.ahj.2021.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2021.04.005</ArticleId><ArticleId IdType="pmc">PMC8057688</ArticleId><ArticleId IdType="pubmed">33891907</ArticleId></ArticleIdList></Reference><Reference><Citation>Sholzberg M, Tang GH, Negri E, Rahhal H, Kreuziger LB, Pompilio CE, et al. . Coagulopathy of hospitalised COVID-19: A pragmatic randomised controlled trial of therapeutic anticoagulation versus standard care as a rapid response to the COVID-19 pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. Trials (2021) 22(1):202. doi: 10.1186/s13063-021-05076-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-021-05076-0</ArticleId><ArticleId IdType="pmc">PMC7943934</ArticleId><ArticleId IdType="pubmed">33691765</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasannan N, Heightman M, Hillman T, Wall E, Bell R, Kessler A, et al. . Impaired exercise capacity in post-COVID syndrome: The role of VWF-ADAMTS13 axis. Blood Adv (2022) 6(13):4041&#x2013;8. doi:&#xa0;10.1182/bloodadvances.2021006944</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021006944</ArticleId><ArticleId IdType="pmc">PMC9098525</ArticleId><ArticleId IdType="pubmed">35543533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricottini E, Nusca A, Ussia GP, Grigioni F. Antithrombotic treatment for valve prostheses: Which drug, which dose, and when? Prog Cardiovasc Dis (2022) 72:4&#x2013;14. doi:&#xa0;10.1016/j.pcad.2022.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcad.2022.05.008</ArticleId><ArticleId IdType="pubmed">35675881</ArticleId></ArticleIdList></Reference><Reference><Citation>Douin DJ, Shaefi S, Brenner SK, Gupta S, Park I, Wright FL, et al. . Tissue plasminogen activator in critically ill adults with COVID-19. Ann Am Thorac Soc (2021) 18(11):1917&#x2013;21. doi:&#xa0;10.1513/AnnalsATS.202102-127RL</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202102-127RL</ArticleId><ArticleId IdType="pmc">PMC8641829</ArticleId><ArticleId IdType="pubmed">33872546</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji HL, Dai Y, Zhao R. Fibrinolytic therapy for COVID-19: a review of case series. Acta Pharmacol Sin (2022) 43(8):2168&#x2013;70. doi:&#xa0;10.1038/s41401-021-00827-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-021-00827-w</ArticleId><ArticleId IdType="pmc">PMC8661828</ArticleId><ArticleId IdType="pubmed">34893684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji HL, Zhao R, Matalon S, Matthay MA. Elevated plasmin (ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev (2020) 100(3):1065&#x2013;75. doi:&#xa0;10.1152/physrev.00013.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00013.2020</ArticleId><ArticleId IdType="pmc">PMC7191627</ArticleId><ArticleId IdType="pubmed">32216698</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett CD, Oren-Grinberg A, Chao E, Moraco AH, Martin MJ, Reddy SH, et al. . Rescue therapy for severe COVID-19-Associated acute respiratory distress syndrome with tissue plasminogen activator: A case series. J Trauma Acute Care Surg (2020) 89(3):453&#x2013;7. doi:&#xa0;10.1097/TA.0000000000002786</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000002786</ArticleId><ArticleId IdType="pmc">PMC7484332</ArticleId><ArticleId IdType="pubmed">32427773</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. . Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost (2020) 18(7):1752&#x2013;5. doi:&#xa0;10.1111/jth.14828</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14828</ArticleId><ArticleId IdType="pmc">PMC7262152</ArticleId><ArticleId IdType="pubmed">32267998</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman N, Bergmeier W, Stouffer GA, Weitz JI. Therapeutic strategies for thrombosis: New targets and approaches. Nat Rev Drug Discovery (2020) 19(5):333&#x2013;52. doi:&#xa0;10.1038/s41573-020-0061-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0061-0</ArticleId><ArticleId IdType="pubmed">32132678</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. . COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-Art review. J Am Coll Cardiol (2020) 75(23):2950&#x2013;73. doi:&#xa0;10.1016/j.jacc.2020.04.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.031</ArticleId><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliter KF, Al-Horani RA. Potential therapeutic benefits of dipyridamole in COVID-19 patients. Curr Pharm Des (2021) 27(6):866&#x2013;75. doi:&#xa0;10.2174/1381612826666201001125604</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612826666201001125604</ArticleId><ArticleId IdType="pmc">PMC7990686</ArticleId><ArticleId IdType="pubmed">33001004</ArticleId></ArticleIdList></Reference><Reference><Citation>Nappi F, Giacinto O, Ellouze O, Nenna A, Avtaar Singh SS, Chello M, et al. . Association between COVID-19 diagnosis and coronary artery thrombosis: A narrative review. Biomedicines (2022) 10(3):702. doi:&#xa0;10.3390/biomedicines10030702</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10030702</ArticleId><ArticleId IdType="pmc">PMC8945192</ArticleId><ArticleId IdType="pubmed">35327504</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaetgens B, Nagy M, Ten Cate H. Antiplatelet therapy in patients with COVID-19-More is less? JAMA (2022) 327(3):223&#x2013;4. doi:&#xa0;10.1001/jama.2021.23866</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.23866</ArticleId><ArticleId IdType="pubmed">35040901</ArticleId></ArticleIdList></Reference><Reference><Citation>Haji Aghajani M, Moradi O, Amini H, Azhdari Tehrani H, Pourheidar E, Rabiei MM, et al. . Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19. J Med Virol (2021) 93(9):5390&#x2013;5. doi:&#xa0;10.1002/jmv.27053</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27053</ArticleId><ArticleId IdType="pmc">PMC8242852</ArticleId><ArticleId IdType="pubmed">33913549</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro F, N&#xfa;&#xf1;ez-Gil IJ, Vitale E, Viana-Llamas MC, Romero R, Maroun Eid C, et al. . Aspirin therapy on prophylactic anticoagulation for patients hospitalized with COVID-19: A propensity score-matched cohort analysis of the HOPE-COVID-19 registry. J Am Heart Assoc (2022) 11(13):e024530. doi:&#xa0;10.1161/JAHA.121.024530</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.024530</ArticleId><ArticleId IdType="pmc">PMC9333361</ArticleId><ArticleId IdType="pubmed">35730631</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro F, Nu&#xf1;ez-Gil IJ, Vitale E, Viana-Llamas MC, Reche-Martinez B, Romero-Pareja R, et al. . Antiplatelet therapy and outcome in COVID-19: the health outcome predictive evaluation registry. Heart (2022) 108(2):130&#x2013;6. doi:&#xa0;10.1136/heartjnl-2021-319552</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2021-319552</ArticleId><ArticleId IdType="pmc">PMC8494537</ArticleId><ArticleId IdType="pubmed">34611045</ArticleId></ArticleIdList></Reference><Reference><Citation>Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, et al. . Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. Am J Hematol (2021) 96(4):471&#x2013;9. doi:&#xa0;10.1002/ajh.26102</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26102</ArticleId><ArticleId IdType="pmc">PMC8013588</ArticleId><ArticleId IdType="pubmed">33476420</ArticleId></ArticleIdList></Reference><Reference><Citation>Viecca M, Radovanovic D, Forleo GB, Santus P. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe COVID-19 and hypercoagulability. a case control, proof of concept study. Pharmacol Res (2020) 158:104950. doi:&#xa0;10.1016/j.phrs.2020.104950</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104950</ArticleId><ArticleId IdType="pmc">PMC7244436</ArticleId><ArticleId IdType="pubmed">32450344</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. . Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med (2020) 217(6):e20200652. doi:&#xa0;10.1084/jem.20200652</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200652</ArticleId><ArticleId IdType="pmc">PMC7161085</ArticleId><ArticleId IdType="pubmed">32302401</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorek M, D&#xfa;brava M, Celec P. On the origin of neutrophil extracellular traps in COVID-19. Front Immunol (2022) 13:821007. doi:&#xa0;10.3389/fimmu.2022.821007</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.821007</ArticleId><ArticleId IdType="pmc">PMC8961727</ArticleId><ArticleId IdType="pubmed">35359960</ArticleId></ArticleIdList></Reference><Reference><Citation>von Br&#xfc;hl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al. . Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med (2012) 209(4):819&#x2013;35. doi:&#xa0;10.1084/jem.20112322</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20112322</ArticleId><ArticleId IdType="pmc">PMC3328366</ArticleId><ArticleId IdType="pubmed">22451716</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer MR, Chen Q, Haldeman S, Yazdani H, Hoffman R, Loughran P, et al. . Deep vein thrombosis in mice is regulated by platelet HMGB1 through release of neutrophil-extracellular traps and DNA. Sci Rep (2018) 8(1):2068. doi:&#xa0;10.1038/s41598-018-20479-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-20479-x</ArticleId><ArticleId IdType="pmc">PMC5794752</ArticleId><ArticleId IdType="pubmed">29391442</ArticleId></ArticleIdList></Reference><Reference><Citation>Denorme F, Portier I, Rustad JL, Cody MJ, de Araujo CV, Hoki C, et al. . Neutrophil extracellular traps regulate ischemic stroke brain injury. J Clin Invest (2022) 132(10):e154225. doi:&#xa0;10.1172/JCI154225</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI154225</ArticleId><ArticleId IdType="pmc">PMC9106355</ArticleId><ArticleId IdType="pubmed">35358095</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser R, Escaig R, Erber J, Nicolai L. Neutrophil-platelet interactions as novel treatment targets in cardiovascular disease. Front Cardiovasc Med (2022) 8:824112. doi:&#xa0;10.3389/fcvm.2021.824112</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.824112</ArticleId><ArticleId IdType="pmc">PMC8841491</ArticleId><ArticleId IdType="pubmed">35174225</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YY, Park HH, Park W, Kim H, Jang JG, Hong KS, et al. . Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm. Biomaterials (2021) 267:120389. doi:&#xa0;10.1016/j.biomaterials.2020.120389</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2020.120389</ArticleId><ArticleId IdType="pmc">PMC7583619</ArticleId><ArticleId IdType="pubmed">33130319</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzetti M, Forastieri A, Borsa N, Pandolfo A, Molteni C, Borghesi L, et al. . IL-1 receptor antagonist anakinra in the treatment of COVID-19 acute respiratory distress syndrome: A retrospective, observational study. J Immunol (2021) 206(7):1569&#x2013;75. doi:&#xa0;10.4049/jimmunol.2001126</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2001126</ArticleId><ArticleId IdType="pmc">PMC7980530</ArticleId><ArticleId IdType="pubmed">33547169</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli G, Dagna L. The course of action for effective anti-cytokine treatment in COVID-19. Lancet Respir Med (2021) 9(12):1353&#x2013;4. doi:&#xa0;10.1016/S2213-2600(21)00405-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00405-7</ArticleId><ArticleId IdType="pmc">PMC8555968</ArticleId><ArticleId IdType="pubmed">34756179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P, et al. . Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol (2021) 3(10):e690&#x2013;7. doi:&#xa0;10.1016/S2665-9913(21)00216-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00216-2</ArticleId><ArticleId IdType="pmc">PMC8352496</ArticleId><ArticleId IdType="pubmed">34396156</ArticleId></ArticleIdList></Reference><Reference><Citation>Vora SM, Lieberman J, Wu H. Inflammasome activation at the crux of severe COVID-19. Nat Rev Immunol (2021) 21(11):694&#x2013;703. doi:&#xa0;10.1038/s41577-021-00588-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00588-x</ArticleId><ArticleId IdType="pmc">PMC8351223</ArticleId><ArticleId IdType="pubmed">34373622</ArticleId></ArticleIdList></Reference><Reference><Citation>Cron RQ, Caricchio R, Chatham WW. Calming the cytokine storm in COVID-19. Nat Med (2021) 27(10):1674&#x2013;5. doi:&#xa0;10.1038/s41591-021-01500-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01500-9</ArticleId><ArticleId IdType="pubmed">34480126</ArticleId></ArticleIdList></Reference><Reference><Citation>Zizzo G, Tamburello A, Castelnovo L, Laria A, Mumoli N, Faggioli PM, et al. . Immunotherapy of COVID-19: Inside and beyond IL-6 signalling. Front Immunol (2022) 13:795315. doi:&#xa0;10.3389/fimmu.2022.795315</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.795315</ArticleId><ArticleId IdType="pmc">PMC8948465</ArticleId><ArticleId IdType="pubmed">35340805</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay MA, Luetkemeyer AF. IL-6 receptor antagonist therapy for patients hospitalized for COVID-19: Who, when, and how? JAMA (2021) 326(6):483&#x2013;5. doi:&#xa0;10.1001/jama.2021.11121</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.11121</ArticleId><ArticleId IdType="pubmed">34228779</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Shao M, Zeng X, Qian P, Huang H. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduct Target Ther (2021) 6(1):367. doi:&#xa0;10.1038/s41392-021-00764-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00764-4</ArticleId><ArticleId IdType="pmc">PMC8526712</ArticleId><ArticleId IdType="pubmed">34667157</ArticleId></ArticleIdList></Reference><Reference><Citation>Siggins MK, Davies K, Fellows R, Thwaites RS, Baillie JK, Semple MG, et al. . Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19. Immunology (2022). doi:&#xa0;10.1111/imm.13585</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13585</ArticleId><ArticleId IdType="pmc">PMC9537932</ArticleId><ArticleId IdType="pubmed">36175370</ArticleId></ArticleIdList></Reference><Reference><Citation>Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, et al. . Complement activation and endothelial perturbation parallel COVID-19 severity and activity. J Autoimmun (2021) 116:102560. doi:&#xa0;10.1016/j.jaut.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020</ArticleId><ArticleId IdType="pmc">PMC7598768</ArticleId><ArticleId IdType="pubmed">33139116</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaldi A, Gritti G, Mic&#xf2; MC, Frigeni M, Borleri G, Salvi A, et al. . Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology (2020) 225(6):152001. doi:&#xa0;10.1016/j.imbio.2020.152001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2020.152001</ArticleId><ArticleId IdType="pmc">PMC7415163</ArticleId><ArticleId IdType="pubmed">32943233</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, Heming N, Grimaldi-Bensouda L, Fr&#xe9;meaux-Bacchi V, Vigan M, Roux AL, et al. . Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. EClinicalMedicine (2020) 28:100590. doi:&#xa0;10.1016/j.eclinm.2020.100590</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100590</ArticleId><ArticleId IdType="pmc">PMC7644240</ArticleId><ArticleId IdType="pubmed">33173853</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. . A living WHO guideline on drugs for covid-19. BMJ (2020) 370:m3379. doi:&#xa0;10.1136/bmj.m3379</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3379</ArticleId><ArticleId IdType="pubmed">32887691</ArticleId></ArticleIdList></Reference><Reference><Citation>Dro&#x17c;d&#x17c;al S, Rosik J, Lechowicz K, Machaj F, Szostak B, Przybyci&#x144;ski J, et al. . An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Update (2021) 59:100794. doi:&#xa0;10.1016/j.drup.2021.100794</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drup.2021.100794</ArticleId><ArticleId IdType="pmc">PMC8654464</ArticleId><ArticleId IdType="pubmed">34991982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund LC, Hedberg P, Andreasen AH, Petersen J, Petersen TS, Potteg&#xe5;rd A, et al. . Prophylactic anticoagulation with low molecular weight heparin in COVID-19: Cohort studies in Denmark and Sweden. Clin Microbiol Infect (2022) 28(9):1291.e1&#x2013;5. doi:&#xa0;10.1016/j.cmi.2022.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.03.006</ArticleId><ArticleId IdType="pmc">PMC8926439</ArticleId><ArticleId IdType="pubmed">35306190</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xfc;ller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, et al. . Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2015) 372(3):232&#x2013;40. doi:&#xa0;10.1056/NEJMoa1405760</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1405760</ArticleId><ArticleId IdType="pmc">PMC4367537</ArticleId><ArticleId IdType="pubmed">25482425</ArticleId></ArticleIdList></Reference><Reference><Citation>Pekrul I, Spannagl M, Nitschmann S. Antikoagulation bei patienten mit COVID-19 [Anticoagulation in patients with COVID-19]. Internist (Berl) (2021) 62(11):1253&#x2013;5. doi:&#xa0;10.1007/s00108-021-01190-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00108-021-01190-y</ArticleId><ArticleId IdType="pmc">PMC8507361</ArticleId><ArticleId IdType="pubmed">34636950</ArticleId></ArticleIdList></Reference><Reference><Citation>Open SAFELY Collaborative. Wong AYS, LA T, JP B, Elson W, AJ W, et al. . Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: Population-based cohort study. J Hematol Oncol (2021) 14(1):172. doi:&#xa0;10.1186/s13045-021-01185-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-021-01185-0</ArticleId><ArticleId IdType="pmc">PMC8525065</ArticleId><ArticleId IdType="pubmed">34666811</ArticleId></ArticleIdList></Reference><Reference><Citation>Attaway AH, Scheraga RG, Bhimraj A, Biehl M, Hatipo&#x11f;lu U. Severe covid-19 pneumonia: Pathogenesis and clinical management. BMJ (2021) 372:n436. doi:&#xa0;10.1136/bmj.n436</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n436</ArticleId><ArticleId IdType="pubmed">33692022</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow JH, Yin Y, Yamane DP, Davison D, Keneally RJ, Hawkins K, et al. . Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: A propensity score-matched analysis. J Thromb Haemost (2021) 19(11):2814&#x2013;24. doi:&#xa0;10.1111/jth.15517</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15517</ArticleId><ArticleId IdType="pmc">PMC8646433</ArticleId><ArticleId IdType="pubmed">34455688</ArticleId></ArticleIdList></Reference><Reference><Citation>Sriram K, Insel PA. Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19? Br J Pharmacol (2020) 177(21):4971&#x2013;4. doi:&#xa0;10.1111/bph.15194</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15194</ArticleId><ArticleId IdType="pmc">PMC7361899</ArticleId><ArticleId IdType="pubmed">32639031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali YM, Ferrari M, Lynch NJ, Yaseen S, Dudler T, Gragerov S, et al. . Lectin pathway mediates complement activation by SARS-CoV-2 proteins. Front Immunol (2021) 12:714511. doi:&#xa0;10.3389/fimmu.2021.714511</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.714511</ArticleId><ArticleId IdType="pmc">PMC8287855</ArticleId><ArticleId IdType="pubmed">34290717</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>